Introduction {#sec1-1}
============

Breast cancer is one of the most common malignancies in women and is considered a genetic disease. Worldwide, there were an estimated 2.1 million cases and 626,679 deaths in 2018 (Bray et al., 2018). In the last few years, breast cancer has been rising progressively, and has now become the most common cancer in women in India with an estimated 1,62,468 incidences and 87,090 mortalities due to breast cancer in 2018 (Cancerindia.org.in, 2018). India has the maximum number of mortalities due to breast cancer than any other country in the world. The reason for this high mortality rate in India is the late detection of breast cancer. Thus, regardless of vast improvement in the overall prognosis and survival rate of patients with noninvasive breast cancer, advanced metastatic breast carcinoma remains a life-threatening disease. One of the major challenges in breast cancer research is now to identify clinically relevant and easily measurable key proteins modulating tumor progression in breast tumors, which can serve as early detection markers for invasive tumors as well as new drug targets. Alteration in expression of key genes through aberrant epigenetic regulation is one of the earliest and most frequent event in tumorigenesis and can contribute to the carcinogenesis and development of breast cancer (Baylin and Ohm, 2006). Epigenetic silencing of different types of genes occurs, including tumor suppressor genes (TSG), DNA repair genes, proapoptotic genes that suppress invasion and metastasis as a result, most of the important cellular network are negatively affected (Jovanovic et al., 2010). Therefore, it has been intensively attempted to exploit the tumor-associated DNA methylation pattern of TSGs for better cancer detection (Gheibi et al., 2012; Sturgeon et al., 2012). Furthermore, in contrast to genetic mutations, an important characteristic of epigenetic modifications such as DNA methylation is that they are potentially reversible and therefore, represent very promising therapeutic targets for breast cancer treatment.

Death-associated protein kinase-1 (DAPK-1) located on chromosome 9q21.33, is an actin associated calcium/calmodulin--dependent enzyme with serine/threonine kinase activity (Cohen et al., 1997). DAPK-1 is mediator of tumor necrosis factor-α, CD95 (Fas), and transforming growth factor-β -induced apoptosis, and has been demonstrated to be an essential mediator in interferon-γ-mediated programmed cell death (Cohen et al., 1999). Furthermore, it suppresses early stage oncogenic transformation by p19ARF-dependent activation of p53 thereby providing an intrinsic p53 dependent apoptotic check (Raveh et al., 2001). As disruption of processes involved in programmed cell death is a common feature of human cancers, it is significant that inactivation of DAPK-1 by hypermethylation has been described in a wide range of cancer cells compared with normal tissues, including lung (Zochbauerr-Muller et al., 2001), head and neck (Rosas et al., 2001), kidney and bladder (Christoph et al., 2006), cervical (Zhao et al., 2008), esophageal (Brock et al., 2003), B cell (Katzenellenbogen et al., 1999) and breast malignancies (Lehmann et al., 2002; Dulaimi et al., 2004; Tan et al., 2012) . DAPK-1 suppresses tumor growth and metastasis by increasing the occurrence of apoptosis in vivo (Inbal et al., 1997). Loss of DAPK-1 expression has been reported to correlate strongly with more aggressive phenotype and poor overall survival rates of several types of human cancer, such as small cell lung cancer, primary head and neck tumors, colon and bladder cancer, multiple myeloma and breast cancer (Gozuacik and Kimchi, 2006).

In the present study, we addressed the role of DAPK-1 promoter methylation in the development of human breast cancer in ethnic Kashmiri population. Our next aim was to demonstrate a correlation between DAPK-1 promoter methylation and loss of protein expression in invasive ductal carcinoma (IDC) subtype of breast cancer that accounts for about 75-- 80% of all breast tumors worldwide. Finally, we aimed to analyze statistical correlations between clinicopathological patient characteristics, DAPK-1 methylation and its expression data.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-1}
--------

Breast tissue samples (n = 128) used for methylation and protein expression analyses were obtained from patients treated by primary surgery for breast cancer in the Department of General Surgery, Sher-I-Kashsmir Institute of Medical Sciences (SKIMS) as per the inclusion and exclusion criteria discussed below.

Inclusion Criteria {#sec2-2}
------------------

The main study inclusion criteria were:

Histologically confirmed Breast Cancer patients undergone mastectomy.Patients who signed the appropriate informed consent form in accordance with local ethical committee guidelines.

Exclusion Criteria {#sec2-3}
------------------

A history of significant or serious uncontrolled cardiovascular disease.Patients unwilling or unable to comply with the protocol.Patients with a history of another primary malignancy that was clinically significant or required active intervention.

All patients were recruited after histopathological diagnosis of breast cancer and all were females. All patients gave informed consent to the study for retention and analysis of their tissue for research purposes approved by the SKIMS Ethical Committee (registration no. SIMS1 31/IEC-SKIMS/2012-6339). Part of the tumour material and macroscopically normal breast (from tissues located at least 3 cm away from the site at which the tumor was sampled) were immediately shock-frozen after surgical resection and stored at −80°C in deep freezer until further analysis. Hematoxylin and eosin (HandE)-stained sections were prepared for assessment of the percentage of tumour cells, only samples with \>80% tumour cells were selected. The normal breast tissue used for standardisation contained approximately 40% of epithelial cells. Histopathological staging was performed according to AJCC-02 TNM staging system and grading was carried out by surgeon according to the Scarff-Bloom- Richardson classification as GI, GII and GIII.

The questionnaire used in the study was well designed to get the finest of the details which were considered to have some relation with our study. Detailed information regarding the patient's medical history was collected from the hospital records of the patient. The questionnaire collected the information on; Clinico-epidemiological characteristics such as age, dwelling, family story of disease, body mass, menopause status, age at menarche, parity, site of tumor, marital status etc.

DNA isolation {#sec2-4}
-------------

Genomic DNA was isolated from tissue samples using proteinase K digestion and organic extractions according to standard procedures. Isolated DNA was resuspended in Tris EDTA buffer (pH 8.0) and stored at −20°C until use. The integrity of the resulting genomic DNA was assessed by low percentage agarose gel electrophoresis and concentration was determined by UV spectrophotometer.

Methylation-specific PCR (MSP) {#sec2-5}
------------------------------

For detection of promoter methylation status, MSP was performed as described earlier (Asiaf et al., 2015; Asiaf et al., 2014). Briefly, extracted DNA was subjected to sodium bisulfite modification using EZ DNA Methylation™ Kit (Zymo Research, USA) according to manufactures protocol. Modified DNA was subjected to MSP using specific primers for methylated sequences (sense 5'-GGATAGTCGGATCGAGTTAACGTC-3' and antisense 5'-CCCTCCCAAACGCCGA- 3') and for unmethylated sequences (sense 5'- GGATAGTTGGATTGAGTTAATGTC -3' and antisense 5'- CAAATCCCTCCCAAACACCAA-3'), which generates polymerase chain reaction (PCR) products of 98 and 106 bp, respectively. The total 25 ml of PCR mix contained 2 ml of bisulfite-modified DNA, 1X PCR buffer, 2 mM MgCl~2~, 200ng of each primer, 0.3 mM dNTPs (Fermentas life sciences, Inc. USA), and 1U of Taq polymerase (Fermentas life sciences, Inc. USA). PCR was carried out in Thermal cycler (Mastercycle, Ependroff) under the following conditions: 95°C for 10 min, followed by 35 cycles of 95°C for 1 min, 64°C for 30 sec, 72°C for 1 min a final extension at 72°C for 10. From each PCR reaction, 8 μl was loaded onto a 3% agarose gel, stained with ethidium bromide and visualized under UV illumination and photographed with Alpha Imager 1,220 v5.5 Camera software. Representative gel pictures are shown in [Figure 1](#F1){ref-type="fig"}. The PCR for all samples demonstrating methylation for the individual genes was repeated to confirm these results.

![MSP Analysis of DAPK1 Gene in Breast Cancer Tissues. Existence of PCR products in lane M indicates the presence of methylation. MSP product in lane U indicates the presence of nonmethylation alleles. In vitro SssI methyltransferase--treated and --untreated DNA from normal lymphocytes were used as the positive controls (PC) for methylation and nonmethylation (NC), respectively. L, 100-bp DNA marker ladder; The methylated allele was detected in Cases 1-3, 5, 7 and 8. Unmethylated allele was detected in Cases 4, 6 and 9.](APJCP-20-839-g001){#F1}

Water blanks were used as a negative control for methylated genes. DNA from peripheral blood lymphocytes of healthy volunteers treated with SssI methyltransferase (New England Biolabs, Beverly, MA, USA) and then subjected to bisulfite modification was used as positive controls for methylated alleles. The reaction was performed in a total volume of 50 μl containing 10 μg of genomic DNA, 10 U of SssI methylase, 160 mM of S-adenosyl-methionine, 50 mM of NaCl, 10 mM of Tris-HCl, 10 mM of MgCl~2~, 1 mM of DTT pH 7.9, during 18 hours at 37°C.

Immunohistochemistry {#sec2-6}
--------------------

Sections of formalin-fixed, paraffin-embedded breast were obtained on polyl-lysine coated slides. Sections were dewaxed in xylene and rehydrated by descending concentrations of ethanol. Slices were subjected to antigen retrieval using microwave heating (20 minutes, citrate buffer pH, 6.0, 10 mM) at 95°C followed by incubation with specific primary antibodies recognizing estrogen receptor (ER) (dilution 1:100; Santacruz Biotechnology Inc., USA), the progesterone receptor (PgR) (1:100 dilution, clone 1A6, Biocare Medical, USA), Her2/neu (sc-08, dilution 1:100; Santacruz Biotechnology Inc., USA) and DAPK-1 (EPR1818(2) dilution 1:200 dilution Abcam) under humid conditions overnight at 4°C. Endogenous peroxidase activity was blocked with 3% H~2~O~2~ for 30 min. Antibodies used in this study were validated (Supplentary file 1).

Next day, the slides were washed three times in Tris buffers (pH 6.0) and bound primary antibody was detected by MACH1 Universal HRP-Polymer (Biocare medical, USA) for 30 min at room temperature. After washing in Tris buffer, the immunostaining reaction product was developed using 3,3-diaminobenzidine (Betazoid DAB Plus substrate, Biocare Medical, USA). After immunoreactivity, slides were dipped in distilled water, counterstained with Harris hematoxyline and finally the sections were dehydrated in xylene, mounted with DPX and coverslipped.

In all cases, adjacent normal surrounding tissue served as an internal positive control. In negative controls, the primary antibody was replaced by non-immune mouse IgG of the same isotype to ensure specificity.

Tumors were classified by intensity of staining and the percentage of cells showing antibody reactivity. The ER and PR sections were scored for the immunohistochemical signal as follows: weak (1+), moderate (2+), and strong (3+) staining in \>10% of the tumor cells or absent (0). Positivity nuclear staining was defined as moderate/strong expression (2+, 3+) in nucleus. For Her2/neu protein expression, membrane immunostaining was considered as positive. Briefly, the scoring system was as follows: no staining or membrane staining in fewer than 10% of tumor cells, 0; faint, barely perceptible membrane staining in more than 10% of tumor cells, the cells are stained only in part of the membrane, 1+; weak to moderate complete membrane staining observed in more than 10% of tumor cells, 2+; and strong, complete membrane staining in more than 10% of tumor cells, 3+ (Rhodes et al., 2002). For DAPK-1 protein expression, the slides were scored numerically by the pathologist on intensity of DAPK-1 cytoplasmic staining (SI; 1 = weak, 2 = moderate, 3 = strong) and the percentage of positive cells (PC; 1 = \< 10%, 2 = 10--50%, 3 = 51--80%, 4 = \> 80%). The product of the two values would result in a composite DAPK-1 score, and the scores were stratified as low = 0--3, intermediate = 4-8, and high = 9-12 (Kuester et al., 2007). For all statistical analyses, the samples were grouped into either DAPK-1 low (0--3) or DAPK-1 medium/high (4, 6, 8, 9, and 12) groups.

Western blotting {#sec2-7}
----------------

Total protein extracts from 56 frozen breast cancer and adjacent normal samples were prepared with lysis buffer (50 mM Tris-HCl, 0.3 M NaCl, 1 mM EDTA and 1 mM dithiothreitol) supplemented with a cocktail of protease inhibitors (Sigma Aldrich, USA). Protein extracts were resolved on SDS-polyacrylamide gels and subsequently electrotransferred onto nitrocellulose membranes (Invitrogen, USA).) in trans-buffer (25 mM Tris; 129 mM glycine; 10% methanol; 0.05% SDS). Membranes were blocked in 5% non-fat milk in 1% TBST for 1 h at room temperature, and incubated overnight at 4°C with a rabbit anti-DAPK1 monoclonal antibody (Abcam, USA) diluted in the same blocking buffer. After washing, membranes were incubated with goat anti-rabbit (Abcam, USA) antibodies conjugated to horseradish peroxidase. Blots were developed with Super Signal chemiluminescence reagent (Pierce). For loading control, membranes were stripped and reprobed with a human-specific antibody against β-actin (Sigma Aldrich, USA). We calculated the DAPK1 protein expression in tumor tissues by normalisation with the corresponding normal tissue lysate taken as 1.0.

Statistical analysis {#sec2-8}
--------------------

The association of gene methylation and DAPK-1 scores with clinical pathological variables was statistically tested using the exact Pearson Chi-squared test. The logistic regression model was used to assess univariate association between DAPK-1 scores (low vs. medium/high), DAPK-1 methylation status (methylated vs. unmethylated) and clinical pathological variables. The variables that were significantly associated with DAPK-1 scores in univariate analysis were then simultaneously put in multivariate logistic regression model to assess the association while adjusting for other significantly associated variables. All p values are two-sided and considered statistically significant at the 0.05 level. All statistical analyses were performed using SPSS (version 16s; SAS Institute; Cary, NC, USA).

Results {#sec1-3}
=======

Clinicopathological findings {#sec2-9}
----------------------------

A total of 128 cases of IDC were included in this study. The mean age of patients was 51.85±1.02 years and median age was 53 (range 26-80). The mean body mass index (BMI) was 23.64±0.21. Age was grouped into two categories with 56.2% of cases lying in the group \>50 years of age. Approximately 68.0% were rural. The stage distribution was typical with 38.3, 31.3, 23.4 and 7 .0 % presenting with Stage I, II, III, and IV respectively. Stage III and IV were combined for all statistical analysis. Most of the tumors were ER-positive (69.5%) and PR positive (66.4%). Her-2-neu immunostaining was detected in only 25% of breast tumors ([Table 1](#T1){ref-type="table"}).

###### 

Clinical and Pathological Characteristics of the Patient Population

  Patients               128
  ---------------------- -------------
  Age(years), mean±SEM   51.85±1.06
   ≤50                   56 (43.8)
   \>50                  72 (56.2)
  Menopausal status      
   Premenopausal         78 (60.9)
   Postmenopausal        50 (39.1)
  Nodal status           
   Negative              79 (61.7)
   Positive              49 (38.3)
  BMI                    23.64± 0.21
   ≤24.9                 67 (52.3)
   25-29.9               37 (28.9)
   ≥30                   24 (18.8)
  Grade                  
   I                     29 (22.6)
   II                    79 (61.7)
   III                   20 (15.6)
  Stage                  
   I                     49 (38.3)
   II                    40 (31.3)
   III                   30 (23.4)
   IV                    9 (7.0)
  Dwelling               
   Rural                 87 (68.0)
   Urban                 41 (32.0)
  Tumor size             
   ≤ 2.0cm               22 (17.2)
   2.1- 4.9cm            59 (46.1)
   ≥ 5cm                 47 (36.7)
  ER-receptor            
   Positive              89 (69.5)
   Negative              39 (30.5)
  PR-receptor            
   Positive              85 (66.4)
   Negative              43 (33.6)
  Her-2-neu              
   Positive              32 (25)
   Negative              96 (75)

Methylation Analysis of DAPK-1 {#sec2-10}
------------------------------

We utilized MS-PCR method to analyze genomic DNA (gDNA) from fresh frozen tissues from patients with invasive ductal carcinoma and normal breast tissue adjacent to tumor for DAPK1 promoter methylation. Representative results for MSP analysis are demonstrated in [Figure 1](#F1){ref-type="fig"}. MSP showed that 37 (29%) of 128 breast tumors were hypermethylated in the DAPK1 promoter region. Accordingly, 71 % of the breast cancer specimens (91/128) exhibited no DAPK1 promoter methylation. On the otherhand, hypermethylation of DAPK1 promoter region was observed in 6(4.6%) of 128 adjacent normal breast tissues. There was a significant difference in the methylation frequency DAPK1 between tumor and normal samples. In all the methylated samples, both unmethylated and methylated PCR products were detected suggesting monoallelic DAPK promoter hypermethylation. Biallelic methylation was not observed in any of the methylated samples.

Epigenetic silencing of DAPK1 protein expression in Breast Cancer {#sec2-11}
-----------------------------------------------------------------

Immunohistochemical analysis of DAPK1 was carried out to determine the effect of promoter methylation on gene silencing and consequent loss of protein expression. Normal breast tissue exhibited positive immunostaining for DAPK1 protein in ductal epithelial cells. Out of 128 tumor samples, 45 (35.2 %), 42 (32.8 %), and 41(32.0 %) had a low, medium, and high DAPK1 score, respectively ([Figure 2](#F2){ref-type="fig"}). Comparison of methylation and Immunohistochemistry data revealed that out of 37 cases exhibiting methylation in DAPK1, 23 (62.2%) showed loss or weak cytoplasmic immunoreactivity for DAPK1 protein. In contrast, in unmethylated group, cytoplasmatic staining with moderate to strong intensity of immunoreactivity was observed in 69 (75.8%) while 22 (24.2%) showed reduced or loss of expression of DAPK1 protein. There was a significant inverse correlation between DAPK1 promoter hypermethylation and loss of its protein (rs= -0.361, p\< 0.001) ([Table 2](#T2){ref-type="table"}).

![Representative Immunostaining Photographs of DAPK in Mammary Gland. Positive staining was identified by the presence of brown staining in the cytoplasm. Cytoplasmic expression of DAPK was observed in normal breast (A), with variable expression in IDCs ranging from strong (IHC score 9-12) (A), intermediate (IHC score 4-8) (B), low (IHC score 0-3) (C) or completely absent (D). Negative control (E) (original magnification- X20).](APJCP-20-839-g002){#F2}

###### 

Correlation between DAPK Methylation and DAPK Expression in Breast Cancer Tissue Samples

  Gene                Loss of expression   Normal expression   OR                CI (95%)      Pvalue     rs
  ------------------- -------------------- ------------------- ----------------- ------------- ---------- ----------
  DAPK methylated     23 (62.2)            14 (37.8)           5.15              2.27- 11.69   \< 0.001   \- 0.361
  DAPK unmethylated   22 (24.2)            69 (75.8)           1.0 (reference)                            

OR odds ratio at 95 % confidence interval (95 % CI); p value from χ2 test; rs Spearman's co-efficient

Correlation analysis between DAPK-1 methylation and clinicopathological parameters of breast cancer {#sec2-12}
---------------------------------------------------------------------------------------------------

Statistical analysis of the correlation of methylation status with clinical and demographic characteristics revealed no significant correlations for the frequency of DAPK1 hypermethylation with menopausal status, dwelling, BMI and tumor grading. A hypermethylated DAPK1 promoter was significantly associated with age at diagnosis (OR = 2.31, CI: 1.02- 5.23, p = 0.041) and tumor stage (p= 0.033). Univariate analysis for DAPK1 hypermethylation between tumor stages demonstrated stage II with an OR= 1.69 (CI: 0.62- 4.60, p= 0.305) and Stage IIIand IV with an OR= 3.43 (CI: 1.31- 8.98, p= 0.01) in comparison to stage I. We did not find an association between DAPK1 methylation and the tumor PR or HER2 status. Estrogen-receptor-negative tumors were associated with higher promoter methylation compared to estrogen-receptor- positive tumors (OR =3.16, CI: 1.41-- 7.09, p = 0.004). Similarly, DAPK1 methylation in breast cancer was strongly associated with triple- negative breast cancers (ER-, PR- and Her2/neu-concomitant triple negative) (O.R.=4.39, C.I.= 1.60- 121.07, p=0.003). Besides, a marginal correlation of DAPK1 promoter hypermethylation with nodal involvement was observed (p= 0.052) ([Table 3](#T3){ref-type="table"}).

###### 

Univariate Logistic Regression for Promoter Methylation Status- Unmethylated (Reference) versus Methylated

  Variable                                      DAPK1 methylation   OR (CI)     P value [(1)](#t3f1){ref-type="table-fn"}   P value [(2)](#t3f2){ref-type="table-fn"}   
  --------------------------------------------- ------------------- ----------- ------------------------------------------- ------------------------------------------- -----------
  Age                                                                                                                                                                   
   ≤50                                          11 (28.6)           45 (71.4)   1 (reference)                               **0.041**                                   **0.041**
   \>50                                         26 (29.2)           46 (70.8)   2.31 (1.02- 5.23)                                                                       
  Menopausal status                             23 (29.5)           55 (70.5)   1 (reference)                               0.862                                       0.862
  Postmenopausal Premenopausal                  14 (28.0)           36 (72.0)   0.93(0.43- 2.04)                                                                        
  Nodal status                                                                                                                                                          
   Negative                                     18(20.3)            61 (79.7)   1 (reference)                               0.052                                       0.052
   Positive                                     19 (42.9)           30 (57.1)   2.15 (0.99- 4.68)                                                                       
  BMI                                                                                                                                                                   
   ≤24.9                                        20 (29.9)           47 (70.1)   1 (reference)                               \-                                          
   25- 29.9                                     10 (27.0)           27 (73.0)   0.87 (0.36- 2.13)                           0.761                                       0.954
   ≥30                                          7 (29.2)            17 (70.8)   0.97 (0.35- 2.69)                           0.95                                        
  Tumor stage                                                                                                                                                           
   I                                            9 (24.5)            40 (75.5)   1(reference)                                \-                                          
   II                                           11 (35.0)           29 (65.0)   1.69 (0.62- 4.60)                           0.305                                       **0.033**
   III and IV                                   17 (28.2)           22 (71.8)   3.43 (1.31- 8.98)                           **0.01**                                    
  Tumor Grade                                                                                                                                                           
   I                                            4 (13.8)            25 (86.2)   1(reference)                                \-                                          
   II                                           28 (35.4)           51 (64.6)   3.43 (1.09- 10.86)                          **0.036**                                   0.082
   III                                          5 (25.0)            15 (75.0)   2.08 (0.483- 8.99)                          0.325                                       
  Dwelling                                                                                                                                                              
   Urban                                        9 (22.0)            32 (78.0)   1 (reference)                               0.233                                       0.233
   Rural                                        28 (32.2)           59 (67.8)   1.69 (0.71- 4.01)                                                                       
  Estrogen receptor                                                                                                                                                     
   Positive                                     19 (21.3)           70 (78.7)   1 (reference)                                                                           
   Negative                                     18 (46.2)           21 (53.8)   3.16 (1.41-7.09)                            **0.004**                                   **0.004**
  Progesterone receptor                                                                                                                                                 
   Positive                                     20 (23.5)           65 (76.5)   1 (reference)                                                                           
   Negative                                     17 (39.5)           26 (60.5)   2.13 (0.96- 4.69)                           0.059                                       0.059
  Her-2-neu                                                                                                                                                             
   Positive                                     11 (34.4)           21 (65.6)   1 (reference)                                                                           
   Negative                                     26 (27.1)           70 (72.9)   0.71 (0.30- 1.67)                           0.431                                       0.431
  ERα /PR/ Her-2-neu status                                                                                                                                             
   Positive [\*](#t3f3){ref-type="table-fn"}    26 (23.9)           83 (76.1)   1 (reference)                               **0.003**                                   **0.003**
   Negative[\*\*](#t3f4){ref-type="table-fn"}   11 (57.9)           8 (42.1)    4.39 (1.60- 12.07)                                                                      

Bold values indicate statistical significance p\<0.05, OR odds ratio calculated at 95 % confidence interval (95 % CI);

Specific level p value,

overall variable p value, p value (two-sided) Pearson's χ2 test;

Positive for any of the 3 receptors (ER/PR/Her2);

Triple negative Breast cancer

Association of DAPK protein expression with clinicopathological parameters {#sec2-13}
--------------------------------------------------------------------------

The association between the expression level of DAPK1 and clinicopatholigical characteristics were parallel to those observed with DAPK1 methylation. Tumors with low or no DAPK1 protein expression showed significant correlation with ER and ER/PR/Her2/neu negativity (p=0.003, O.R.= 3.16, C.I.=1.44--6.92; p=0.024, O.R.=3.03, C.I.=1.12--8.22) respectively. Univariate analysis for low DAPK1 expression between breast tumor stages demonstrated stage II tumors with an OR = 3.79 (1.42-- 10.13, p = 0.008) and stage III andIV tumors with an OR = 5.40 (2.02- 14.43, p = 0.001) compared to stage I tumors. There were no significant correlations of immunohistochemically estimated DAPK1 protein expression with menopausal status, age, dwelling, BMI, tumor differentiation, and lymph node metastasis ([Table 4](#T4){ref-type="table"}. In the multivariate analysis ([Table 5](#T5){ref-type="table"}), low or no expression of DAPK1 was found to be associated with advanced tumor stage (p = 0.005) only and not with ER negativity (p= 0.092) and triple negative breast cancer (p= 0.589).

###### 

Univariate Logistic Regression for DAPK Expression- Low versus Normal (Reference)

  Variable                                      Normal Low   OR (95% CI)   P value [(1)](#t4f1){ref-type="table-fn"}   P value [(2)](#t4f2){ref-type="table-fn"}   
  --------------------------------------------- ------------ ------------- ------------------------------------------- ------------------------------------------- -----------
  Age                                                                                                                                                              
   ≤50                                          37 (66.1)    19 (33.9)     1 (reference)                                                                           
   \>50                                         46 (63.9)    26 (36.1)     1.10 (0.53-2.30)                            0.798                                       0.798
  Menopausal status                                                                                                                                                
   Postmenopausal                               52 (66.7)    26 (33.3)     1 (reference)                                                                           
   Premenopausal                                31 (62.0)    19 (38.0)     0.82 (0.39- 1.71)                           0.59                                        0.59
  Nodal status                                                                                                                                                     
   Negative                                     55 (69.6)    24 (30.4)     1(reference)                                0.151                                       0.151
   Positive                                     28 (57.1)    21 (42.9)     1.72 (0.82- 3.61)                                                                       
  BMI                                                                                                                                                              
   ≤ 24.9                                       39 (58.2)    28 (41.8)     1(reference)                                \-                                          
   25- 29.9                                     25 (67.6)    12 (32.4)     0.67 (0.29- 1.55)                           0.349                                       0.167
   ≥ 30                                         19 (79.2)    5 (20.8)      0.37 (0.12- 1.10)                           0.073                                       
  Tumor stage                                                                                                                                                      
   I                                            41 (83.7)    8 (16.3)      1(reference)                                \-                                          
   II                                           23 (57.5)    17 (42.5)     3.79 (1.42 -- 10.13)                        **0.008**                                   **0.001**
   III and IV                                   19 (48.7)    20 (51.3)     5.40 (2.02- 14.43)                          **0.001**                                   
  Tumor Grade                                                                                                                                                      
   I                                            20 (69.0)    9 (31.0)      1(reference)                                \-                                          
   II                                           46 (58.2)    33 (41.8)     1.59 (0.65- 3.94)                           0.312                                       0.071
   III                                          17 (85.0)    3 (15.0)      0.39 (0.09- 1.69)                           0.208                                       
  Dwelling                                                                                                                                                         
   Urban                                        28 (68.3)    13 (31.7)     1(reference)                                0.575                                       0.575
   Rural                                        55 (63.2)    32 (36.8)     1.25 (0.57- 2.76)                                                                       
  Estrogen receptor                                                                                                                                                
   Positive                                     65 (73.0)    24 (27.0)     1(reference)                                                                            
   Negative                                     18 (46.2)    21 (53.8)     3.16 (1.44- 6.92)                           **0.003**                                   **0.003**
  Progesterone receptor                                                                                                                                            
   Positive                                     60 (70.6)    25 (29.4)     1(reference)                                0.56                                        0.56
   Negative                                     23 (53.5)    20 (46.5)     2.09 (0.98- 4.46)                                                                       
  Her-2-neu                                                                                                                                                        
   Positive                                     22 (68.8)    10 (31.2)     1(reference)                                0.593                                       0.593
   Negative                                     61 (63.5)    35 (36.5)     1.26 (0.54- 2.97)                                                                       
  ER/PR/Her-2-neu status                                                                                                                                           
   Positive[\*](#t4f3){ref-type="table-fn"}     75 (68.8)    34 (31.2)     1(reference)                                **0.024**                                   **0.024**
   Negative[\*\*](#t4f4){ref-type="table-fn"}   8 (42.1)     11 (57.9)     3.03 (1.12- 8.22)                                                                       

Bold values indicate statistical significance p\<0.05, OR odds ratio calculated at 95 % confidence interval (95 % CI);

Specific level p value,

overall variable p value, p value (two-sided) Pearson's χ2 test ;

Positive for any of the 3 receptors (ER/PR/Her2);

, Triple negative Breast cancer.

Expression of DAPK1 in Breast tissues using western blotting {#sec2-14}
------------------------------------------------------------

We also examined DAPK1 expression by Western blotting in 56 frozen breast cancer and adjacent normal samples to confirm the results obtained by immunohistochemistry showing association between DAPK1 promoter methylation and its impaired synthesis. Among 56 IDC tumor tissues 23 were methylated and 33 were unmethylated. Out of 23 methylated tumors, 16 expressed loss or marked reduction of DAPK1 expression, whereas the remaining seven tumors expressed similar amounts of DAPK1 compared with their matching normal tissues. In contrast, 22 of the 33 unmethylated tumors expressed amounts of DAPK1 similar to those expressed by their corresponding normal tissues. Only 11 unmethylated tumors showed reduced expression of DAPK1 compared to their normal counterpart. Representative examples are shown in [Figure 3](#F3){ref-type="fig"}. These results confirmed that hypermethylation of the CpG islands located in the promoter region of the DAPK1 gene is associated with loss of DAPK1 expression of protein in breast cancer tissues as observed by immunohistochemistry analysis. A significant positive correlation between the immunohistochemical results and the western blotting values for DAPK1 ([Figure 4](#F4){ref-type="fig"}) was observed.

![The Representative Western Blot Shows the Expression of DAPK1 Protein Using the DAPK1 Antibody. Lane 1: (T1) Breast tumor tissue lysate(40 µg), lane 2: (N1) Normal breast tissue lysate(40 µg), lane 3: (T2) Breast tumor tissue lysate (40 µg) lane 4: (N2) Normal breast tissue lysate (40 µg), lane 5: pB513B1-DAPK1 transfected HEK cell lysate (10 µg), lane 6: pB513B1-DAPK1 transfected HEK cell lysate (20 µg), lane73:pB513B1-DAPK1 transfected HEK cell lysate (40 µg),](APJCP-20-839-g003){#F3}

![Relationship between Western Blotting Values and Immunohistochemical Expression Analysis of DAPK1 in IDCs of Breast Using Pearson Correlation Test.](APJCP-20-839-g004){#F4}

Discussion {#sec1-4}
==========

DAPK1 has a critical role in regulating apoptosis under normal growth conditions that is highlighted by the fact that tumor cells utilize multiple mechanisms to evade DAPK1 mediated cell death, thus creating permissive environment for accumulation of genetic instabilities and promoting the initiation and progression of cancer. Thus, it becomes our ultimate goal to gain a deeper insight into the mechanisms involved in DAPK1 regulation, as this may assist in the design of suitable therapeutic regimens to enable the outcome of cell fate decisions in tumor cells to be tipped in favour of apoptosis.

An earlier investigation analysing DAPK1 methylation in different histological subtypes of breast cancer, reported that, lobular invasive breast carcinomas exhibit a high level of DAPK1 loss of expression (mRNA) and promoter hypermethylation (53%) whereas, only 9% of their 85 invasive ductal carcinoma specimens showed promoter hypermethylation (Lehmann et al., 2002). Another study analyzed methylation of DAPK1 in breast tumor and paired preoperative serum DNA and detected promoter hypermethylation in 40% of invasive ductal carcinoma breast tumor samples (Dulaimi et al., 2004). Furthermore, we demonstrated a significant difference in hypermethylation frequency between cancerous tissues and the corresponding normal breast tissues. These data collectively suggest that the methylation of DAPK1 promoter is a tumor-specific phenomenon. However, the presence of hypermethylation in some adjacent non-cancerous tissues represents field defect of premalignant changes that occurs early in carcinogenesis. The fact about the adjacent normal breast tissues that they lack microscopic evidence of malignancy suggests that these changes are not transforming themselves. However, they might allow the prospective acquisition and accumulation of other genetic and epigenetic changes that do, in time, lead to malignancy in spatio-temporal manner. Alternatively, there may be a threshold level for hypermethylation to affect protein expression of gene and lead to a growth advantage.

###### 

Multivariable Logistic Regression for DAPK Expression-Low (Reference) versus Medium/High

  Variable                 OR (CI 95%)          P value
  ------------------------ -------------------- -----------
  Tumor Stage                                   
   I                       1                    **0.005**
   II                      3.35 (1.22- 9.21)    
   III & IV                5.27 (1.92- 14.46)   
  Estrogen receptor                             
   Positive                1                    0.092
   Negative                2.46 (0.86---7.03)   
  ER/PR/Her-2-neu status                        
   Negative                1                    0.589
   Positive                1.45 (0.38- 5.53)    

p value from χ^2^ test, bold values indicate statistical significance p\<0.05; OR odds ratio at 95 % confidence interval (95 % CI).

The methylation of CpG islands located within the promoter region is generally associated with a decrease in protein expression or a loss of protein expression (Baylln et al., 1997; Esteller, 2008). In fact, in this study, the occurrence of DAPK1 promoter hypermethylation correlated strongly with a marked decrease in protein expression suggesting that DNA hypermethylation may be the probable inactivation mechanism of this gene in breast tumors. However, a decreased DAPK1 immunostaining in 24.2% of cases without DAPK1 methylation may be due to other mechanisms, such as gene mutation and loss of heterozygosity (LOH) or promoter homozygous deletions of CpG island which have also been shown to be involved in the regulation of DAPK1 expression in breast and other cancer as well (Simpson et al., 2002; Raveh and Kimchi, 2001). Furthermore, for some methylated cases, we observed a complete loss of DAPK1 protein expression, even though a biallelic methylation was ever obtained by MS-PCR. In these cases, accompanying unmethylated PCR products might be the result of contamination with inflammatory cells and surrounding stroma. To the best of our knowledge, this is the first comprehensive study reporting loss of DAPK1 protein expression associated with DAPK1 promoter methylation in invasive ductal carcinoma subtype of Kashmiri breast cancer patients.

The number of clearly different molecular phenotypes of breast tumors suggests that much is unknown regarding the diversity of these neoplasms. Triple-negative breast cancers (TNBC) represent 10-17% of all breast malignancies, occur in young women, and are associated with a high risk of early relapse and poor survival (Yuan et al., 2014). In our study, significant association was observed between loss of DAPK1 protein expression and ER negativity and triple negative phenotype. Although we did not perform a survival analysis in our patients, these findings demonstrate that loss of DAPK1 is associated with poor prognosis in breast cancer. However, this result warrants confirmation because the group of patients with triple negative phenotype was small (n = 19), moreover, while loss of DAPK1 expression appeared to be associated with triple negative breast cancers in univariate analysis, this association could not be confirmed on the multivariate analysis and may require a larger dataset to evaluate this. Our data that loss of DAPK1 expression is associated with ER negativity and triple negative phenotype corroborate the earlier findings who also found either decreased expression or increased hypermethylation of DAPK1 in these phenotypes (Levy et al., 2004; Hafez et al., 2015).

Moreover, we found a significant positive correlation between DAPK1 methylation and age at diagnosis in our large cohort (n = 128) of breast cancer patients. Promoter methylation in several genes increases with age in normal tissues, although the exact impact of aging in methylation status remains unknown (Issa and Ahuja, 2000). In addition we could show a significantly higher DAPK1 promoter hypermethylation and weaker DAPK1 protein expression in tumor of higher stages relative to less advanced stage tumors. Similarly, higher hypermethylation of DAPK gene was observed in more advanced stage of cervical cancer (Narayan et al., 2003). This increased loss of protein expression with advanced tumor invasiveness and tumor stage supports the potential protective function of DAPK1 against tumor progression and metastasis in breast carcinogenesis. No further correlations between DAPK1 methylation and other clinicopathological parameters were found, except the marginal correlation with nodal status.

Based on the differences in the expression of DAPK1 between groups with distinct prognostic characteristics, we hypothesize that the immunohistochemical evaluation of this marker predicts tumor progression. However, additional studies that address these specific issues must be performed.

In conclusion, taken together, our analysis regarding aberrant DAPK-1 promoter methylation and DAPK-1 expression lead to the following conclusions: DAPK-1 is indeed a tumour suppressor gene in normal breast tissue, which undergoes epigenetical silencing during breast tumorigenesis. The methylation status of DAPK-1 predicts poor prognosis and could serve as a prognostic biomarker in human breast cancer. However, the clinical significance of our preliminary findings should be further confirmed in large cohorts that will undoubtedly lead to a greater understanding of breast cancer progression and may help to establish therapeutic strategies for patients with breast cancer.
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